Observation as the initial management strategy in patients with mantle cell lymphoma
暂无分享,去创建一个
R. Gascoyne | D. Scott | L. Sehn | A. Mottok | P. Abrisqueta | K. Savage | G. Slack | C. Steidl | J. Connors | D. Villa | A. Gerrie | David W. Scott | K. J. Savage
[1] L. Staudt,et al. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] W. Klapper,et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.
[3] A. Jemal,et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma , 2016, Cancer.
[4] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[5] F. d'Amore,et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. , 2013, Blood.
[6] E. Giné,et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.
[7] E. Giné,et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.
[8] R. Warnke,et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior , 2012, Haematologica.
[9] R. Lai,et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis , 2011, Haematologica.
[10] A. Rosenwald,et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.
[11] H. Eve,et al. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Leonard,et al. Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[14] W. Klapper,et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. , 2008, Blood.
[15] S. Swerdlow,et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. , 2003, Human pathology.
[16] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[17] D. Catovsky,et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.
[18] L. Staudt,et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.
[19] D. Catovsky,et al. Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia , 2002, British journal of haematology.
[20] C. Kittas,et al. The splenic form of mantle cell lymphoma , 2002, European journal of haematology.
[21] T. Habermann,et al. Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma , 2001, Leukemia & lymphoma.
[22] P. Cohen,et al. Bone marrow and peripheral blood involvement in mantle cell lymphoma , 1998, British journal of haematology.
[23] H. Tilly,et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.